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To the Editor,
The Vascular Endothelial Growth Factor European 
Genomic Federation (VEGF) Consortium (www.vegfcon-
sortium.org) was founded in June 2014 by Sophie Visvikis-
Siest (chair of the consortium) and an international group 
of researchers with an interest focused on VEGF-A and its 
implications in personalized medicine.
Here, we present the VEGF Consortium and describe 
its objectives and ambitions, its structure and its compo-
nents together with the methodologies used in projects 
and preliminary results.
The VEGF Consortium aims to develop a transna-
tional collaborative network dedicated to large inte-
grative and multidisciplinary genomic studies of the 
VEGF-A in order to generate applicable knowledge 
for medical practice thanks to the following specific 
objectives:
 – to combine data from multiple cohorts in order to 
identify VEGF-A ‘-omics’ profiling in health and non-
communicable diseases
 – to elucidate the pivotal role of VEGF-A in the patho-
physiology of non-communicable diseases
 – to demonstrate the patients’ stratification potential of 
VEGF-A ‘-omics’ profiling
 – to implement the research results into clinical prac-
tice and establish the role of VEGF-A as a predictive, 
preventive, diagnostic and prognostic biomarker
 – to provide information on the effect of VEGF-A 
‘-omics’ profiling in side effects and response to ther-
apy through pharmacogenomics studies
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 – to propose implementation strategies and European 
guidelines involving VEGF-A ‘-omics’ profiling for the 
management of non-communicable diseases
 – to share methodologies, data and knowledge in 
the field of ‘-omics’ management and innovative 
statistics
 – to develop standardized teaching and evaluation 
methods practiced and validated by the consortium.
It comprises 11 working groups, where the partners of the 
consortium are participating based on their expertise:
1. VEGF-A ‘-omics’ profiling in health
2. VEGF-A ‘-omics’ profiling in diseases
3. ‘-Omics’ technologies
4. Methodological aspects
5. VEGF-A clinical implementation
6. Pharmagenomics
7. Endothelins and endothelial factors
8. VEGF-A basic research (cancer cell lines, animal 
models)
9. VEGF-A and inflammation
10. Communication and scientific/educational meetings
11. Raising awareness of populations
Prospective, longitudinal, family-based or population-
based cohorts of healthy individuals are the core of the 
consortium. These are the following:
1. The STANISLAS family study: This is a longitudinal 
family structure cohort of community-based popula-
tion of French origin recruited in 1993–1995, followed 
up for 15  years. A number of 1006 nuclear families 
comprising two parents and at least two biological 
children over 6 years old are included in the study [1].
2. The Framingham Heart Study: It is an ongoing, lon-
gitudinal, community-based, observational cohort 
study that was initiated in 1948 to prospectively 
investigate the risk factors for cardiovascular disease 
(CVD). The original cohort enrolled 5209  men and 
women, the offspring cohort enrolled 5124 partici-
pants (including 3514 biological offspring) and Gen 
3 included 4095 individuals [2–4].
3. Cilento study: This is a population-based study that 
aims at identifying genetic risk factors for common 
diseases and traits. The sample includes isolated 
populations from three villages (Campora, Gioi and 
Cardile). The overall sample size of individuals par-
ticipating to the study is 2100 [5].
4. The LifeLines Cohort Study and Biobank (LLs): LLs 
is a multidisciplinary prospective population-based 
cohort study examining the health and health-related 
behaviors of 167,000 persons living in the north east 
region of The Netherlands in a three-generation 
design [6].
Furthermore, cohorts of patients and case-control studies 
are also included in the consortium:
5. The Hellenic Study of Interactions between SNPs 
and  Eating in Atherosclerosis Susceptibility: case-
control study of coronary artery disease.
6. Ljubljana patients: case-control studies recruited 
from Ljubljana, Slovenia that include cases of osteo-
porosis, osteoarthritis, CVD and diabetes [7–9].
In addition, partners of the consortium have access 
to large  biobanks such as the UK Biobank (Panagio-
tis Deloukas), Biobanking and Biomolecular Resources 
Research Infrastructure – European Research Infrastruc-
ture Consortium BBMRI-ERIC (including Sophie Visvi-
kis-Siest with the Biological Resources Center IGE-PCV 
– BB-0033-00051) and the Alliance for Clinical Trials in 
Oncology (Federico Innocenti).
Given the wide range of the research field and the 
need for application of different methodologies in order 
to successfully achieve its objectives, the consortium is 
composed of scientists with different and complementary 
expertise and with a large range of resources such as large 
study populations, research materials and harmonized 
data.
Although the VEGF Consortium was officially 
founded on 2014, it was based on the long-term collabo-
ration between some of its founding partners. Therefore, 
a number of significant results have been published 
already, and many projects are ongoing, with promising 
preliminary results.
Among the most basic steps was the identification 
through two genome-wide association studies (GWAS) of 
10 genetic variants that explain >50% of the circulating 
VEGF-A levels variability [10, 11]. This is a unique finding 
among GWAS. In most GWAS, the identified variants do 
not explain >10% of the individual variability of the 
assessed traits. This finding has strengthened our belief 
that VEGF-A will indeed be used as strong biomarker 
for personalized medicine. Significant associations 
between some of these polymorphisms and intermedi-
ate phenotypes of chronic diseases have been identified 
since then: high-density and low-density lipoprotein 
[12], L-selectin gene expression [13] and free tri-iodothy-
ronin (FT3) levels [14]. Significant epistatic interactions 
between these variants were observed for intercellular 
adhesion molecule 1 (ICAM-1), E-selectin, interleukin 
6 and tumor necrosis factor α (TNF-α) plasma levels 
[13]. Concerning specific disease risk, we have shown 
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that these polymorphisms and/or their epistatic inter-
actions can affect the risk for depression [15], and for 
autoimmune thyroid diseases [14], whereas no associa-
tions were found for diabetes type 2 [16].
Concerning the expression isoforms of VEGF-A gene, 
we have shown that these are significantly associated 
with ICAM-1, L-selectin and TNF-α expression [13] and 
with specific autoimmune thyroid diseases [17].
Furthermore, we have also identified associations 
between VEGF-A circulating levels and thyroid hormones 
levels [17] and with ICAM-1 and E-selectin levels [13].
Through a candidate gene approach of polymor-
phisms in genes involved in angiogenesis, we have identi-
fied direct and epistatic effects of variants on nitric oxide 
synthase 3 (NOS3), CD14+ monocytes, matrix metallopro-
teinases (MMPs) and interleukin 4 receptor (ILR4) genes 
with levels of VEGF-A and VEGF-A expression isoforms, 
but also gene × environment interactions [18].
An important result is also the production of two 
patents based on the results of studies performed by part-
ners of the consortium [19, 20].
Several projects are ongoing and focused on CVD 
intermediate phenotypes, thyroid diseases, cancer and 
stroke.
Three face-to-face meetings have been organized to 
date: Paris (2014), Budapest (2015) and Santorini (2016).
The VEGF Consortium is an ambitious international 
collaboration that aims to pave the way for the implemen-
tation of VEGF-A in personalized medicine and routine 
clinical practice. The designed projects take advantage 
of the wide expertise of its partners, the large infrastruc-
tures of cohorts and biobanks and a combination of the 
most up-to-date “-omics” approaches for generating 
multidimensional data, as well as ‘systems medicine’ 
approaches, network analysis and computational mod-
eling methodologies.
Among its major originalities is that it integrates 
commercialization and communication platforms, tar-
geting the valid and easy measurement of the identified 
biomarkers in large-scale settings but also the education 
of the general population, patients, scientists and health 
practitioners.
The VEGF Consortium is a novel consortium with 
an innovating structure and original goals. The ultimate 
goal is to ameliorate life expectancy, quality of life for 
individuals and financial benefits for health systems.
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